What the 2026 ADA Consensus Statement Says About GLP-1s in Type 2 Diabetes

The American Diabetes Association's annual consensus statement on diabetes care is one of the most-referenced guidance documents in the field. The 2026 version reflects continued evolution in how GLP-1 medications are positioned within type 2 diabetes management. Here's what changed.

The Standing Recommendation

ADA guidance has increasingly positioned GLP-1 receptor agonists as first-line or early-consideration therapy for type 2 diabetes patients with cardiovascular disease, chronic kidney disease, or overweight/obesity — moving away from the historical framing where GLP-1s came in later in the treatment algorithm.

The 2026 update reinforces this direction while adding nuance based on the evolving evidence for specific agents in specific comorbidity populations.

New in 2026

The 2026 statement incorporates updates from SURMOUNT-MMO (cardiovascular outcomes for tirzepatide), FLOW follow-up (renal outcomes for semaglutide), and STEP-HFpEF (heart failure with preserved ejection fraction). Guidance now specifies preferential considerations for one agent over another based on comorbidity profile, rather than treating all GLP-1s as interchangeable.

The oral GLP-1 category (Rybelsus, Wegovy pill) is more explicitly addressed than in prior versions, with recommendations on when oral options are appropriate first-line versus when injectable is preferred.

The Combination Therapy Section

Combination with SGLT2 inhibitors receives expanded discussion. In patients with type 2 diabetes and either established CVD or CKD, the statement supports concurrent use of both classes based on complementary mechanisms and evidence of additive benefit.

Combination with metformin remains standard. The historical framing of metformin as universal first-line has softened somewhat — in patients with strong indications for GLP-1 therapy (obesity, CVD, CKD), starting with a GLP-1 rather than metformin is now viewed as reasonable.

Prior Authorization and Access Guidance

The 2026 statement includes explicit acknowledgment of access and cost barriers. Guidance addresses how prescribers should navigate prior authorization requirements, document medical necessity, and consider generic and compounded alternatives when brand-name access is limited.

This is unusual for a clinical consensus statement — it reflects the reality that in the current US healthcare environment, coverage barriers materially affect prescribing decisions, and prescribers benefit from guidance on navigating them.

What the Statement Doesn't Address

The statement is diabetes-focused, so it doesn't directly address use of GLP-1s for weight management in patients without diabetes. That falls under obesity medicine guidance. It also doesn't take positions on compounded product legality or safety — that's outside ADA's scope, though the access section indirectly acknowledges the compounded market's existence.

Where to Start